A 68-year-old man with COPD presents to the emergency department with acute onset of severe mydriasis, cycloplegia, tachycardia (HR 128/min), dry mouth, and confusion. He had been using ipratropium bromide inhaler 4 times daily for the past 3 days following a respiratory exacerbation. On examination, his pupils are 8 mm and non-reactive to light. What is the most appropriate immediate next step in management?

Explanation

## Clinical Diagnosis This patient presents with acute anticholinergic toxicity (anticholinergic crisis) secondary to excessive ipratropium use. The constellation of mydriasis, cycloplegia, tachycardia, dry mouth, and altered mental status (confusion) is pathognomonic for anticholinergic poisoning. **Key Point:** Anticholinergic toxicity is a medical emergency requiring specific antidote therapy, not supportive care alone. ## Mechanism of Anticholinergic Toxicity Ipratropium is a quaternary ammonium anticholinergic agent used in COPD. Excessive inhalation or systemic absorption (especially in elderly patients with reduced clearance) leads to: - Blockade of muscarinic acetylcholine receptors - Loss of parasympathetic tone - Unopposed sympathetic activity (tachycardia, hypertension) - CNS effects: confusion, agitation, hallucinations, seizures (in severe cases) ## Management Algorithm ```mermaid flowchart TD A[Anticholinergic Toxicity Suspected]:::outcome --> B{Severity?}:::decision B -->|Mild: dry mouth, mild tachycardia| C[Supportive care, monitor]:::action B -->|Moderate-Severe: CNS involvement, severe tachycardia| D[Administer Physostigmine]:::action D --> E[IV physostigmine 1-2 mg slowly over 5 min]:::action E --> F[Repeat every 5-10 min if needed]:::action F --> G[Monitor for cholinergic crisis]:::decision G -->|Improvement| H[Continue supportive care]:::action G -->|Worsening| I[Prepare atropine for reversal]:::urgent ``` ## Why Physostigmine? **High-Yield:** Physostigmine is a tertiary amine anticholinesterase that crosses the blood–brain barrier, making it the only agent effective for **central anticholinergic effects** (confusion, agitation, hallucinations). | Feature | Physostigmine | Neostigmine | Edrophonium | |---------|---|---|---| | **BBB penetration** | Yes (tertiary amine) | No (quaternary amine) | No | | **CNS effects reversal** | Yes | No | No | | **Onset** | 3–8 minutes (IV) | 7–15 minutes | 30–60 seconds | | **Duration** | 30–60 minutes | 2–8 hours | 5–10 minutes | | **Use in anticholinergic toxicity** | **First-line** | Not indicated | Not indicated | **Clinical Pearl:** Physostigmine is contraindicated in anticholinergic toxicity caused by **atropine or other tertiary amines** if there is concurrent cardiac dysrhythmia or conduction block, but in this case (ipratropium-induced), it is safe and indicated. **Warning:** Do NOT use neostigmine or edrophonium — they cannot cross the BBB and will not reverse CNS symptoms. Atropine is a **contraindication** because it would worsen the anticholinergic state. ## Dosing & Monitoring 1. **Physostigmine IV:** 1–2 mg slow IV push over 5 minutes 2. **Repeat:** Every 5–10 minutes if symptoms persist (max cumulative dose ~4 mg) 3. **Monitor:** HR, BP, pupil size, mental status, respiratory effort 4. **Watch for:** Cholinergic crisis (excessive salivation, bronchospasm, bradycardia) — treat with atropine if occurs [cite:KD Tripathi 8e Ch 7]